Preclinical & CMC Services for AAV-Based Ocular Gene Therapies
Capabilities
From Preclinical Research to Clinical-Ready AAV Manufacturing
Pharmaron provides end-to-end preclinical and CMC services for AAV-based ocular therapies, ensuring efficacy, biodistribution, safety, and regulatory compliance. With over a decade of experience in ocular gene therapy development, our team supports IND, IMPD, and BLA submissions through high-quality preclinical studies and scalable AAV manufacturing.
We specialize in AAV preclinical testing for retinal and ocular diseases, with GLP toxicology studies, biodistribution analysis, and functional endpoints evaluation. Our state-of-the-art CMC facility delivers high-purity AAV manufacturing with chromatography-based purification and scalable suspension culture systems.
Key Preclinical & CMC Capabilities:
With expertise in preclinical ocular AAV studies and CMC regulatory pathways, Pharmaron ensures successful AAV gene therapy development from discovery to market.
Why Choose Pharmaron for Ocular AAV Development?
- Over a Decade of Experience in Ocular Gene Therapy – Supporting IND & clinical submissions worldwide
- Regulatory-Ready Preclinical & CMC Support – Ensuring smooth transition from research to market approval
- State-of-the-Art GMP AAV Manufacturing – Scalable, high-purity ocular gene therapy production
Optimize your AAV gene therapy for ocular diseases. Download our service overview to explore Pharmaron’s preclinical & CMC solutions.